BioSpace News Archive

The U.S. Food and Drug Administration is providing an update on additional steps it has taken that will lead to more infant formula available in the U.S.

Lyell Immunopharma, Inc. announced that members of its senior management team will present at the Credit Suisse 31st Annual Healthcare Conference Wednesday, November 9, at 2:00 p.m. ET.

Intelligent Bio Solutions Inc. announced that it will release its financial results for the first quarter ended September 30, 2022, shortly after the NASDAQ market close on Wednesday, November 9.

Societal CDMO, Inc. announced that the company will release financial results for the third quarter 2022 after the market close on Wednesday, November 9, 2022.

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter that ended September 30, 2022, on Monday, November 7, 2022, after the close of the U.S. financial markets.

Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate in the Credit Suisse 31st Annual Healthcare Conference.

Inari Medical, Inc., a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, reported financial results for its third quarter ended September 30, 2022.

Omnicell, Inc. today announced results for its third quarter ended September 30, 2022 and updated 2022 guidance.

NTT Research, Inc., a division of NTT (TYO:9432), today announced that the collaboration between its Medical & Health Informatics (MEI) Lab and the Technical University of Munich (TUM) has produced a novel technique for closed-loop control of innervated tissue of a live insect.

OrsoBio, Inc. today announced its acquisition of assets relating to the Liver X Receptor (LXR) inverse agonist program from Phenex Pharmaceuticals, including lead candidate TLC-2716 and associated intellectual property.